Solid Tumor Market: By Drug Class, By Disease Indications, and Region Forecast 2020-2031

download arrow download arrow Download Sample
settings arrow settings arrow email us

Solid Tumor Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Class (Antimetabolites, MAbs, Inhibitor, Mitotic Inhibitors, Multichines Inhibitors, antineoplastics), By Disease Indications ( Lung cancer, Breast cancer, Prostate cancer, Cervical cancer, Colorectal cancer, Others), and Region Forecast 2020-2031

checked icon checked icon arrow_drop_down
checked icon Single User License $4400 $3520
checked icon Multiple User License $6600 $5280
checked icon Corporate User License $8900 $7120

1. Executive Summary
2. Global Solid Tumor Market Introduction
2.1. Global Solid Tumor Market - Taxonomy
2.2. Global Solid Tumor Market -Definitions
2.2.1. By Drug Class
2.2.2. By Disease Indications
2.2.3. By Region
3. Global Solid Tumor Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Solid Tumor Market Dynamic Factors - Impact Analysis
3.6. Impact of COVID 19 on The Market
3.7. Three Forecast Scenarios - Pessimistic, Conservative, and Opportunistic
3.8. Mapping Market Players’ Activities
3.9. Recent Key Developments
3.10. Financial Status of the Market Players
3.11. Recent Acquisitions, Collaborations, and Mergers
4. Global Solid Tumor Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Solid Tumor Market Forecast, By Drug Class, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million)
5.1. Antimetabolites
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. MAbs
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. XPO1 Inhibitor
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Mitotic Inhibitors
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Multikinase Inhibitors
5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Antineoplastics
5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. Global Solid Tumor Market Forecast, By Disease Indications, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million)
6.1. Lung cancer
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Breast cancer
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Prostate cancer
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Cervical cancer
6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Colorectal cancer
6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Others
6.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
7. Global Solid Tumor Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million)
7.1. North America
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Solid Tumor Market - Opportunity Analysis Index, By Drug Class, Disease Indications, and Region, 2023 - 2029
8. North America Solid Tumor Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million)
8.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%)
8.1.1. Antimetabolities
8.1.2. MAbs
8.1.3. XPO1 Inhibitor
8.1.4. Mitotic Inhibitors
8.1.5. Multikinase Inhibitors
8.1.6. antineoplastics
8.2. Disease Indications Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%)
8.2.1. Lung cancer
8.2.2. Breast cancer
8.2.3. Prostate cancer
8.2.4. Cervical cancer
8.2.5. Colorectal cancer
8.2.6. Others
8.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million) Y-o-Y Growth (%) and Market Share (%)
8.3.1. U.S.
8.3.2. Canada
8.4. North America Solid Tumor Market - Opportunity Analysis Index, By Drug Class, Disease Indications and Country, 2023 - 2029
8.5. North America Solid Tumor Market Dynamics - Trends
9. Europe Solid Tumor Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million)
9.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%)
9.1.1. Antimetabolities
9.1.2. MAbs
9.1.3. XPO1 Inhibitor
9.1.4. Mitotic Inhibitors
9.1.5. Multikinase Inhibitors
9.1.6. antineoplastics
9.2. Disease Indications Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Lung cancer
9.2.2. Breast cancer
9.2.3. Prostate cancer
9.2.4. Cervical cancer
9.2.5. Colorectal cancer
9.2.6. Others
9.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million) Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Europe Solid Tumor Market - Opportunity Analysis Index, By Drug Class, Disease Indications and Country, 2023 - 2029
9.5. Europe Solid Tumor Market Dynamics - Trends
10. Asia-Pacific Solid Tumor Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million)
10.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%)
10.1.1. Antimetabolities
10.1.2. MAbs
10.1.3. XPO1 Inhibitor
10.1.4. Mitotic Inhibitors
10.1.5. Multikinase Inhibitors
10.1.6. antineoplastics
10.2. Disease Indications Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Lung cancer
10.2.2. Breast cancer
10.2.3. Prostate cancer
10.2.4. Cervical cancer
10.2.5. Colorectal cancer
10.2.6. Others
10.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million) Y-o-Y Growth (%) and Market Share (%)
10.3.1. Japan
10.3.2. China
10.3.3. India
10.3.4. ASEAN
10.3.5. Rest of Asia-Pacific
10.4. Asia-Pacific Solid Tumor Market - Opportunity Analysis Index, By Drug Class, Disease Indications and Country, 2023 - 2029
10.5. Asia-Pacific Solid Tumor Market Dynamics - Trends
11. Latin America Solid Tumor Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million)
11.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%)
11.1.1. Antimetabolities
11.1.2. MAbs
11.1.3. XPO1 Inhibitor
11.1.4. Mitotic Inhibitors
11.1.5. Multikinase Inhibitors
11.1.6. antineoplastics
11.2. Disease Indications Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Lung cancer
11.2.2. Breast cancer
11.2.3. Prostate cancer
11.2.4. Cervical cancer
11.2.5. Colorectal cancer
11.2.6. Others
11.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million) Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Argentina
11.3.3. Rest of Latin America
11.4. Latin America Solid Tumor Market - Opportunity Analysis Index, By Drug Class, Disease Indications and Country, 2023 - 2029
11.5. Latin America Solid Tumor Market Dynamics - Trends
12. Middle East and Africa Solid Tumor Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million)
12.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%)
12.1.1. Antimetabolities
12.1.2. MAbs
12.1.3. XPO1 Inhibitor
12.1.4. Mitotic Inhibitors
12.1.5. Multikinase Inhibitors
12.1.6. antineoplastics
12.2. Disease Indications Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Lung cancer
12.2.2. Breast cancer
12.2.3. Prostate cancer
12.2.4. Cervical cancer
12.2.5. Colorectal cancer
12.2.6. Others
12.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million) Y-o-Y Growth (%) and Market Share (%)
12.3.1. Saudi Arabia
12.3.2. GCC Countries
12.3.3. South Africa
12.3.4. Rest of MEA
12.4. MEA Solid Tumor Market - Opportunity Analysis Index, By Drug Class, Disease Indications and Country, 2023 - 2029
12.5. MEA Solid Tumor Market Dynamics - Trends
13. Competition Landscape 
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Drug Class Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Abbott Laboratories Inc.
13.2.2. Biogen Inc.
13.2.3. AstraZeneca PLC
13.2.4. Boehringer Ingelheim GmbH
13.2.5. Amgen Inc.
13.2.6. Bristol-Myers Squibb Company
13.2.7. Stemline Therapeutics, Inc.
13.2.8. Baxter International Inc.
13.2.9. Eli Lilly and Company
13.2.10. F. Hoffmann-La Roche AG
13.2.11. GlaxoSmithKline PLC
14. Research Methodology
15. Key Assumptions and Acronyms

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Download Free Sample Report

I accept the Terms and Conditions,Disclaimers, GDPR Policy

Frequently Asked Questions

The solid tumor market key players are: Abbott Laboratories Inc., Biogen Inc., AstraZeneca PLC, Boehringer Ingelheim GmbH, Amgen Inc., Bristol-Myers Squibb Company, Stemline Therapeutics, Inc., Baxter International Inc., Eli Lilly and Company, GlaxoSmithKline PLC, Hoffmann-La Roche AG

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

Key Market Players

  •  Abbott Laboratories Inc.
  • Biogen Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Stemline Therapeutics, Inc.
  • Baxter International Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Hoffmann-La Roche AG

Related Industry Reports

Oncology Software Market

Computer-Aided Drug Discovery Market

Intraoperative Fluorescence Imaging Market

Cancer Tumour Profiling Market